Is chaos in US health policy creating new global opportunities? With major leadership and policy shake-ups the US healthcare ...

Connecting 80+ EHS experts in pharma and biopharma on the West coast, this year's meeting will address the challenges of ...

The increasing incidence of genetic and rare diseases is a major factor driving revenue growth in the Antisense ...

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build next-gen central nervous system drugs. | Big Biotech Biogen is venturing into ...

Dravet syndrome is a severe form of epilepsy, usually diagnosed in infancy, that is associated with developmental delays and severe seizures. It has long been recognized for its neurological symptoms, ...

A new gene replacement therapy for Dravet syndrome alleviated symptoms in mice, offering hope for more effective human treatments. Further research is needed.

" Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures ...

Biogen and Stoke Therapeutics have reached an agreement to develop and commercialize zorevunersen, a potential first-in-class disease-modifying therapy for Dravet syndrome, in all regions outside of ...

Biogen gains rights to Stoke’s Dravet syndrome candidate in deal worth $550m The rare genetic epilepsy affects up to 38,000 people in the US, UK, EU and Japan Biogen and Stoke Therapeutics have ...

CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ: BIIB), a prominent biotechnology company with a $20.1 billion market cap currently trading near its 52-week low, and Stoke Therapeutics, Inc. (NASDAQ: STOK) ...

Biogen has entered a collaboration with Stoke Therapeutics to develop and commercialise zorevunersen to treat Dravet syndrome in all territories outside Canada, Mexico, and the US.